Blog Will the Supreme Court Review Whether FDA-Mandated Bioequivalence Testing to Maintain Approval Falls Within the § 271(e)(1) Safe Harbor? August 15, 2016
Blog Federal Circuit: A Biosimilar Applicant Must Provide Notice of Intent to Market a Biosimilar Product, No Exceptions July 20, 2016
Event Avoiding and Utilizing Prosecution History in Litigation, Prosecution, and Due Diligence October 9, 2018